Grasp-Release Assessment of a Networked Neuroprosthesis Device (GRANND)

July 19, 2023 updated by: Kevin Kilgore, MetroHealth Medical Center
The overall objective of this trial is to characterize the safety and effectiveness of the Networked Neuroprosthesis Device - Upper Extremity (NP-UE) in individuals living with cervical SCI.

Study Overview

Detailed Description

The Networked Neuroprosthesis(NNP) is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals. The NNP-UE Configuration activates nerves of the upper extremity (arm and hand), and senses voluntary motion and/or electromyogram (EMG) in order to provide hand grasp.

The proposed work is focused on restoration of hand and reaching functions for people with cervical level spinal cord injury. For individuals who have sustained this injury, restoration of hand function is their top priority, and existing alternatives are limited. Neuroprosthesis are the most promising method for significant gain in hand and arm function.

Study Type

Interventional

Enrollment (Estimated)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Ohio
      • Cleveland, Ohio, United States, 44109
        • Recruiting
        • MetroHealth Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female, age > 16 years.
  • Cervical level spinal cord injury, as defined by:

    1. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor level of C1 through C7 and
    2. American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade A, B, or C;
  • Six months or more post-injury (neurostability);
  • Neurologically stable following any nerve transfers affecting the upper extremity (typically, one year post surgery);
  • Musculoskeletally and neurologically stable following any tendon transfers affecting the upper extremity (typically, 6-months).
  • Peripheral nerve innervation to upper extremity muscles, including a grade 3/5 or higher Stimulated Manual Muscle Test (SMMT) strength in at least two of the following muscles in one arm:

    1. Adductor Pollicus, Abductor Pollicus Brevis (AbPB), Flexor Pollicus Longus (FPL), Extensor Pollicus Longus (EPL)/Extensor Pollicus Brevis (EPB), Extensor Digitorum Communis (EDC), Flexor Digitorum Superficialis (FDS), Flexor Digitorum Profundus (FDP), Pronator Quadratus (PQ), Extensor Carpi Ulnaris (ECU), Extensor Carpi Radialis Brevis (ECRB), Extensor Carpi Radialis Longus (ECRL), Flexor Carpi Ulnaris (FCU), Flexor Carpi Radialis (FCR), First Dorsal Interosseous(1DI), triceps,
    2. At least two of the grade 3/5 or higher excitable muscles must also have grade 2/5 or lower voluntary strength;
  • Good proximal upper extremity strength as defined by biceps/brachialis/brachioradialis strength of 2/5 or higher on Manual Muscle Test on the side intended for implantation;
  • Medically stable;
  • Able to understand and provide informed consent.

Exclusion Criteria:

  • Other neurological conditions (MS(multiple Sclerosis), diabetes with peripheral nerve involvement); Associated peripheral nerve / brachial plexus injury
  • Progressive SCI;
  • Co-existing cervical spine pathology (syrinx, unstable segment)
  • Active implantable medical device (AIMD) such as a pacemaker or defibrillator;
  • Active untreated infection such as pressure injury, urinary tract infection, pneumonia;
  • History of coagulopathy, HIV, cardiopulmonary disease, bradycardia, poorly controlled autonomic dysreflexia, or chronic obstructive pulmonary disease that would preclude safe participation in the trial as determined by the investigator;
  • Unhealed fractures that prevent functional use of arm;
  • Extensive upper extremity denervation (fewer than two excitable hand muscles);
  • Involvement in other ongoing clinical studies that exclude concurrent involvement in this study;
  • Disorder or condition that requires MRI monitoring;
  • Mechanical ventilator dependency;
  • Currently pregnant (neuroprosthesis implantation delayed until no longer pregnant);
  • Presence of disease that might interfere with participant safety, compliance, or evaluation of the condition under study;
  • Other significant medical findings that, in the opinion of the investigator, preclude safe participation in the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental: Intervention - implant neuroprosthesis
Receives implanted networked neuroprosthetic system for arm and hand function. Undergoes functional training and assessment.
The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Grasp-Release Test
Time Frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
Ability to pick up, move, and release six standard objects
Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Grasp Dynameter(force)
Time Frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
Measure of muscular strength or the maximum force/tension generated by one's forearm muscles.
Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
Change in Canadian Occupational Performance Measure (COPM)
Time Frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
Evidence-based outcome measure designed to capture a client's self-perception of performance in everyday living, over time
Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
Change in Activities of Daily Living (ADL) Abilities Test
Time Frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
The Activities of Daily Living (ADL) profile uses both observation and interview to assess function in tasks completed in the personal, home, and community environments.
Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
Change in Spinal Cord Independence Measure III (SCIM-III)
Time Frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant
The measure address three specific areas of function in patients with spinal cord injuries (SCI). It looks at self-care (feeding, grooming, bathing, and dressing), respiration and sphincter management, and a patient's mobility abilities (bed and transfers and indoors/outdoors)
Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anne Bryden, PhD, OTR/L, MetroHealth Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 23, 2022

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

April 1, 2027

Study Registration Dates

First Submitted

April 28, 2023

First Submitted That Met QC Criteria

May 8, 2023

First Posted (Actual)

May 18, 2023

Study Record Updates

Last Update Posted (Actual)

July 21, 2023

Last Update Submitted That Met QC Criteria

July 19, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Cord Injuries

Clinical Trials on Networked Neuroprosthesis Device

3
Subscribe